FDA Seeks To Enhance Reporting Of Pediatric Adverse Events
This article was originally published in The Pink Sheet Daily
Executive Summary
In addition to the Adverse Event Reporting System, FDA may collect pediatric safety data from other surveillance databases and Phase IV trials. Options to improve safety reporting will be a topic for future discussion by the Pediatric Advisory Committee.
You may also be interested in...
Pediatric Adverse Event Reporting Could Improve With Claims Database Analysis
FDA’s Pediatric Advisory Committee says the easiest short-term remedy for improving the quality of the agency’s adverse event reporting system would be claims database analysis, although the best method would be population-based active surveillance.
Pediatric Adverse Event Reporting Could Improve With Claims Database Analysis
FDA’s Pediatric Advisory Committee says the easiest short-term remedy for improving the quality of the agency’s adverse event reporting system would be claims database analysis, although the best method would be population-based active surveillance.
Antidepressant “Black Box” Warning For Pediatric Suicidality Risk Recommended
“Black box” warning would encourage discussion of risks and benefits of antidepressant therapy in children by physicians, FDA advisory committee members say. Warning likely to affect direct-to-consumer advertising, FDA notes. Committee members recommend class warning for all antidepressants, including new products.